3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia
2
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Cardiotoxicity
1
Burkitt Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Doxorubicin
6
Dexrazoxane
6
Razoxane
5
Vincristine
4
Cyclophosphamide
4
Radiotherapy
3
Etoposide
3
Prednisone
2
Methotrexate
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Carvedilol
2
Bleomycin
2
schizandrin
1
pegfilgrastim
1
hydrocortisone hemisuccinate
1
fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
1
empagliflozin
1
Watchful Waiting
1
VAP-cyclo protocol
1
Trastuzumab
1
Taxes
1
Tamoxifen
1
Rituximab
1
Ramipril
1
Radiation
1
Prednisolone
1
Paclitaxel
1
Observation
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Cardiotoxicity
×
hydrocortisone hemisuccinate
×
Clear all
NCT01230983
2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3
Completed
573 enrolled